The role of uric acid and other crystals in osteoarthritis

Current Rheumatology Reports

Volumn 12, Issue 2, 2010, Pages 142-148

  Nowatzky, Johannes ^a   Howard, Rennie ^a   Pillinger, Michael H ^a   Krasnokutsky, Svetlana ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Calcium pyrophosphate; Crystal arthropathy; Osteoarthritis; Uric acid

Indexed keywords

CALCIUM PHOSPHATE; CALCIUM PYROPHOSPHATE; CHONDROITIN 4 SULFATE; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 8; SILICON DIOXIDE; URATE; URIC ACID;

BONE EROSION; BYSTANDER EFFECT; CARTILAGE DEGENERATION; CRYSTALLIZATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; GOUT; HUMAN; HYPERURICEMIA; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; REVIEW; SYNOVITIS; URIC ACID BLOOD LEVEL;

CALCIUM PYROPHOSPHATE; CRYSTALLIZATION; GOUT; HUMANS; JOINTS; OSTEOARTHRITIS; URIC ACID;

EID: 77953477888     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0091-4     Document Type: Review

References (56)

1. Doherty M, Dieppe P: Clinical aspects of calcium pyrophosphate dehydrate crystal deposition. Rheum Dis Clin North Am 1988, 14:395-414.
2. Roddy E, Zhang W, Doherty M: Gout and nodal osteoarthritis: a case-control study. Rheumatology (Oxford) 2008, 47:732-733. This was one of the rare studies that investigated a possible relationship between gout and OA as its primary objective.
3. Anderson JJ, Felson DT: Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988, 128:179-189.
4. Felson DT, Zhang Y, Anthony JM, et al.: Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992, 116:535-539.
5. Schouten JS, van den Ouweland FA, Valkenburg HA: A 12 year follow up study in the general population on prognostic factors of cartilage loss in osteoarthritis of the knee. Ann Rheum Dis 1992, 51:932-937.
6. Sun Y, Brenner H, Sauerland S, et al.: Serum uric acid and patterns of radiographic osteoarthritis - the Ulm Osteoarthritis Study. Scand J Rheumatol 2000, 29:380-386. (Pubitemid 32014837)
7. Acheson RM, Collart AB: New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population. Ann Rheum Dis 1975, 34:379-387.
8. Lally EV, Ho G Jr, Kaplan SR: The clinical spectrum of gouty arthritis in women. Arch Intern Med 1986, 146:2221-2225.
9. Simkin PA, Campbell PM, Larson EB: Gout in Heberden's nodes. Arthritis Rheum 1983, 26:94-97.
10. Lally EV, Zimmermann B, Ho G Jr, Kaplan SR: Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989, 32:86-90.
11. Roddy E, Zhang W, Doherty M: Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis 2007, 66:1374-1377.
12. Laurent TC: Solubility of sodium urate in the presence of chondroitin-4-sulphate. Nature 1964, 202:1334.
13. Katz WA, Schubert M: The interaction of monosodium urate with connective tissue components. J Clin Invest 1970, 49:1783-1789.
14. Burt HM, Dutt YC: Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis 1986, 45:858-864.
15. Muehleman C, Li J, Aigner T, et al.: Association between crystals and cartilage degeneration in the ankle. J Rheumatol 2008, 35:1108-1117. This was a large, well-designed study investigating the prevalence, histologic, and biomechanical effects of MSU and CPP crystals on cartilage in the human ankle. A predominantly biomechanical effect was found to be induced by both MSU and CCP crystals.
16. Malawista SE, Duff GW, Atkins E, et al.: Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum 1985, 28:1039-1046.
17. Di Giovine FS, Malawista SE, Nuki G, Duff GW: Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987, 138:3213-3218.
18. Gowen M, Wood DD, Ihrie EJ, et al.: An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983, 306:378-380. (Pubitemid 14242749)
19. Heath JK, Saklatvala J, Meikle MC, et al.: Pig interleukin 1 (catabolin) is a potent stimulator of bone resorption in vitro. Calcif Tissue Int 1985, 37:95-97.
20. Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936-2946.
21. Martinon F, Pétrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
22. Alwan WH, Dieppe PA, Elson CJ, Bradfield JW: Hydroxyapatite and urate crystal induced cytokine release by macrophages. Ann Rheum Dis 1989, 48:476-482.
23. Smith MD, Triantafillou S, Parker A, et al.: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365-371.
24. Warnock MG, Sharif M, Elson CJ: IL-1-beta at physiological concentration stimulates degradation of human articular cartilage. Bone Miner 1994; 25(Suppl):S36.
25. Liu R, Lioté F, Rose DM, et al.: Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum 2004, 50:247-258.
26. Abramson SB: Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008, 10(Suppl 2):S2.
27. Liu L, Inoue H, Nakayama H, et al.: The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. Pathobiology 2007, 74:177-185. This article introduced a new and important concept.
28. Benko S, Philpott DJ, Girardin SE: The microbial and danger signals that activate NOD-like receptors. Cytokine 2008, 43: 368-373.
29. Gasse P, Riteau N, Charron S, et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179:903-913.
30. Behrens MD, Wagner WM, Krco CJ, et al.: The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008, 111:1472-1479.
31. Stabler TV, Heinrichs A, McDaniel G, et al.: Synovial fluid uric acid as a marker of joint tissue degradation in osteoarthritis [abstract]. Osteoarthr Cartil 2009, 17:S68-S69.
32. Zitnan D, Sitaj S: Chondrocalcinosis polyarticularis (familiaris): roentgenological and clinical analysis. Cesk Rentgenol 1960, 14:27-34.
33. Derfus BA, Kurian JB, Butler JJ, et al.: The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002, 29:570-574.
34. Pattrick M, Hamilton E, Wilson R, et al.: Association of radiographic changes of osteoarthritis, symptoms, and synovial fluid particles in 300 knees. Ann Rheum Dis 1993, 52:97-103.
35. Neame RL, Carr AJ, Muir K, Doherty M: UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003, 62:513-518.
36. Felson DT, Anderson JJ, Naimark A, et al.: The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol 1989, 16:1241-1245.
37. Sanmarti R, Kanterewicz E, Pladevall M, et al.: Analysis of the association between chondrocalcinosis and osteoarthritis: a community based study. Ann Rheum Dis 1996, 55:30-33.
38. Zhang Y, Terkeltaub R, Nevitt M, et al.: Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study Arthritis Rheum 2006, 54:3508-3512.
39. Silcox DC, McCarty DJ Jr: Elevated inorganic pyrophosphate concentrations in synovial fluids in osteoarthritis and pseudogout. J Lab Clin Med 1974, 83:518-531.
40. Derfus B, Kranendonk S, Camacho N, et al.: Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 1998, 63:258-262.
41. Halverson PB: Calcium crystal-associated diseases. Curr Opin Rheumatol 1996, 8:259-261.
42. Doherty M, Dieppe P: Clinical aspects of calcium pyrophosphate dihydrate crystal deposition. Rheum Dis Clin North Am 1988, 14:395-414.
43. Fam AG, Morava-Protzner I, Purcell C, et al.: Acceleration of experimental lapine osteoarthritis by calcium pyrophosphate microcrystalline synovitis. Arthritis Rheum 1995, 38:201-210.
44. Cheung HS, Story MT, McCarty DJ: Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystals on cultured mammalian cells. Arthritis Rheum 1984, 27:668-674.
45. Hachicha M, Naccache PH, McColl SR: Inflammatory micro-crystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995, 182:2019-2025.
46. Liu YZ, Jackson AP, Cosgrove SD: Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthr Cartil 2009, 17:1333-1340. This was a particularly valuable study investigating the effects of synthetic and native CPP crystals on human chondrocytes and synoviocytes.
47. Whelan LC, Morgan MP, McCarthy GM: Basic calcium phosphate crystals as a unique therapeutic target in osteoarthritis. Front Biosci 2005, 10:530-541.
48. Fuerst M, Bertrand J, Lammers L, et al.: Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009, 60:2694-2703. This was a cartilage calcification study of 120 patients undergoing total knee replacement. It found BCP crystals in 100% of specimens and postulated the new idea of BCP calcification as an integral part of OA pathogenesis.
49. Pritzker KP: Counterpoint: Hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis. Curr Rheumatol Rep 2009, 11:148-153.
50. Oliviero F, Frallonardo P, Peruzzo L, et al.: Evidence of silicon dioxide crystals in synovial fluid of patients with osteoarthritis. J Rheumatol 2008, 35:1092-1095.
51. Grassi W, Meenagh G, Pascual E, Filippucci E: "Crystal clear"-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum 2006, 36:197-202.
52. Dalbeth N, McQueen FM: Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol 2009, 21:124-131.
53. Schueller-Weidekamm C, Schueller G, Aringer M, et al.: Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007, 62:437-443.
54. Perez-Ruiz F, Martin I, Canteli B: Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007, 34:1888-1893.
55. Thiele RG, Schlesinger N: Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007, 46:1116-1121. This article intro-duced specific diagnostic features for the detection of MSU crystals by ultrasonography.
56. Puig JG, de Miguel E, Castillo MC, et al.: Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008, 27:592-595.